Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of “Moderate Buy” by Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $41.40.

Several research analysts have issued reports on the stock. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. HC Wainwright assumed coverage on shares of Hemab Therapeutics in a report on Wednesday, June 17th. They issued a “buy” rating and a $40.00 target price for the company. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 target price for the company. Finally, Jefferies Financial Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price for the company.

Insider Buying and Selling at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the acquisition, the director directly owned 6,149,096 shares of the company’s stock, valued at approximately $110,683,728. This trade represents a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have purchased 2,970,541 shares of company stock worth $55,459,603 over the last three months.

Hemab Therapeutics Stock Performance

Shares of Hemab Therapeutics stock opened at $31.74 on Tuesday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.